Update on the Role of Autologous Hematopoietic Stem Cell Transplantation in Follicular Lymphoma

Update on the Role of Autologous Hematopoietic Stem Cell Transplantation in Follicular Lymphoma

Follicular lymphoma (FL) remains incurable despite advances in new strategies of treatment, including monoclonal antibodies (MoAb). Except for early stages, FL is characterized by responses to treatments and systematic relapses. The main objective in this disease is to achieve a better progression f...

Full description

Bibliographic Details
Main Authors: Cabrero, Mónica, Redondo, Alba, Martin, Alejandro, Caballero, Dolores
Format: Online
Language:English
Published: Università Cattolica del Sacro Cuore 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507525/
id pubmed-3507525
recordtype oai_dc
spelling pubmed-35075252012-11-30 Update on the Role of Autologous Hematopoietic Stem Cell Transplantation in Follicular Lymphoma Cabrero, Mónica Redondo, Alba Martin, Alejandro Caballero, Dolores Review Articles Follicular lymphoma (FL) remains incurable despite advances in new strategies of treatment, including monoclonal antibodies (MoAb). Except for early stages, FL is characterized by responses to treatments and systematic relapses. The main objective in this disease is to achieve a better progression free survival (PFS) and to increase overall survival (OS), mainly in young patients. In order to improve the results of conventional chemotherapy, autologous stem cell transplant (ASCT) is a feasible treatment in these patients. In this moment, ASCT is not recommended as first line treatment, except for transformed FL, but is a good strategy as salvage therapy with an improved PFS and OS. New drugs have been introduced to enhance responses of ASCT, but nowadays they are not part of conventional conditioning regimen. Università Cattolica del Sacro Cuore 2012-11-07 /pmc/articles/PMC3507525/ /pubmed/23205262 http://dx.doi.org/10.4084/MJHID.2012.074 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Cabrero, Mónica
Redondo, Alba
Martin, Alejandro
Caballero, Dolores
spellingShingle Cabrero, Mónica
Redondo, Alba
Martin, Alejandro
Caballero, Dolores
Update on the Role of Autologous Hematopoietic Stem Cell Transplantation in Follicular Lymphoma
author_facet Cabrero, Mónica
Redondo, Alba
Martin, Alejandro
Caballero, Dolores
author_sort Cabrero, Mónica
title Update on the Role of Autologous Hematopoietic Stem Cell Transplantation in Follicular Lymphoma
title_short Update on the Role of Autologous Hematopoietic Stem Cell Transplantation in Follicular Lymphoma
title_full Update on the Role of Autologous Hematopoietic Stem Cell Transplantation in Follicular Lymphoma
title_fullStr Update on the Role of Autologous Hematopoietic Stem Cell Transplantation in Follicular Lymphoma
title_full_unstemmed Update on the Role of Autologous Hematopoietic Stem Cell Transplantation in Follicular Lymphoma
title_sort update on the role of autologous hematopoietic stem cell transplantation in follicular lymphoma
description Follicular lymphoma (FL) remains incurable despite advances in new strategies of treatment, including monoclonal antibodies (MoAb). Except for early stages, FL is characterized by responses to treatments and systematic relapses. The main objective in this disease is to achieve a better progression free survival (PFS) and to increase overall survival (OS), mainly in young patients. In order to improve the results of conventional chemotherapy, autologous stem cell transplant (ASCT) is a feasible treatment in these patients. In this moment, ASCT is not recommended as first line treatment, except for transformed FL, but is a good strategy as salvage therapy with an improved PFS and OS. New drugs have been introduced to enhance responses of ASCT, but nowadays they are not part of conventional conditioning regimen.
publisher Università Cattolica del Sacro Cuore
publishDate 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507525/
_version_ 1611935756084838400

Similar Items